List of Excipients in API avapritinib
✉ Email this page to a colleague
Excipients in NDA-approved (novel) drugs containing avapritinib
| Company | Tradename | Ingredient | NDC | Excipient | Potential Generic Entry |
|---|---|---|---|---|---|
| Blueprint Medicines Corporation | AYVAKIT | avapritinib | 72064-110 | AMMONIA | 2034-10-15 |
| Blueprint Medicines Corporation | AYVAKIT | avapritinib | 72064-110 | BUTYL ALCOHOL | 2034-10-15 |
| Blueprint Medicines Corporation | AYVAKIT | avapritinib | 72064-110 | CELLULOSE, MICROCRYSTALLINE | 2034-10-15 |
| Blueprint Medicines Corporation | AYVAKIT | avapritinib | 72064-110 | COPOVIDONE K25-31 | 2034-10-15 |
| Blueprint Medicines Corporation | AYVAKIT | avapritinib | 72064-110 | CROSCARMELLOSE SODIUM | 2034-10-15 |
| Blueprint Medicines Corporation | AYVAKIT | avapritinib | 72064-110 | FD&C BLUE NO. 1 | 2034-10-15 |
| >Company | >Tradename | >Ingredient | >NDC | >Excipient | >Potential Generic Entry |
Detailed excipient profiles for avapritinib
Excipient focus: AMMONIA
avapritinib drug variants containing AMMONIA
| Company | Ingredient | NDC |
|---|---|---|
| Blueprint Medicines Corporation | avapritinib | 72064-110 |
| >Company | >Ingredient | >NDC |
avapritinib drug variants not containing AMMONIA
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: BUTYL ALCOHOL
avapritinib drug variants containing BUTYL ALCOHOL
| Company | Ingredient | NDC |
|---|---|---|
| Blueprint Medicines Corporation | avapritinib | 72064-110 |
| >Company | >Ingredient | >NDC |
avapritinib drug variants not containing BUTYL ALCOHOL
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: CELLULOSE, MICROCRYSTALLINE
avapritinib drug variants containing CELLULOSE, MICROCRYSTALLINE
| Company | Ingredient | NDC |
|---|---|---|
| Blueprint Medicines Corporation | avapritinib | 72064-110 |
| >Company | >Ingredient | >NDC |
avapritinib drug variants not containing CELLULOSE, MICROCRYSTALLINE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: COPOVIDONE K25-31
avapritinib drug variants containing COPOVIDONE K25-31
| Company | Ingredient | NDC |
|---|---|---|
| Blueprint Medicines Corporation | avapritinib | 72064-110 |
| >Company | >Ingredient | >NDC |
avapritinib drug variants not containing COPOVIDONE K25-31
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: CROSCARMELLOSE SODIUM
avapritinib drug variants containing CROSCARMELLOSE SODIUM
| Company | Ingredient | NDC |
|---|---|---|
| Blueprint Medicines Corporation | avapritinib | 72064-110 |
| >Company | >Ingredient | >NDC |
avapritinib drug variants not containing CROSCARMELLOSE SODIUM
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: FD&C BLUE NO. 1
avapritinib drug variants containing FD&C BLUE NO. 1
| Company | Ingredient | NDC |
|---|---|---|
| Blueprint Medicines Corporation | avapritinib | 72064-110 |
| >Company | >Ingredient | >NDC |
avapritinib drug variants not containing FD&C BLUE NO. 1
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: FERROSOFERRIC OXIDE
avapritinib drug variants containing FERROSOFERRIC OXIDE
| Company | Ingredient | NDC |
|---|---|---|
| Blueprint Medicines Corporation | avapritinib | 72064-110 |
| >Company | >Ingredient | >NDC |
avapritinib drug variants not containing FERROSOFERRIC OXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: ISOPROPYL ALCOHOL
avapritinib drug variants containing ISOPROPYL ALCOHOL
| Company | Ingredient | NDC |
|---|---|---|
| Blueprint Medicines Corporation | avapritinib | 72064-110 |
| >Company | >Ingredient | >NDC |
avapritinib drug variants not containing ISOPROPYL ALCOHOL
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: MAGNESIUM STEARATE
avapritinib drug variants containing MAGNESIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| Blueprint Medicines Corporation | avapritinib | 72064-110 |
| >Company | >Ingredient | >NDC |
avapritinib drug variants not containing MAGNESIUM STEARATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: MICROCRYSTALLINE CELLULOSE 101
avapritinib drug variants containing MICROCRYSTALLINE CELLULOSE 101
| Company | Ingredient | NDC |
|---|---|---|
| Blueprint Medicines Corporation | avapritinib | 72064-110 |
| >Company | >Ingredient | >NDC |
avapritinib drug variants not containing MICROCRYSTALLINE CELLULOSE 101
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: POLYETHYLENE GLYCOL 4000
avapritinib drug variants containing POLYETHYLENE GLYCOL 4000
| Company | Ingredient | NDC |
|---|---|---|
| Blueprint Medicines Corporation | avapritinib | 72064-110 |
| >Company | >Ingredient | >NDC |
avapritinib drug variants not containing POLYETHYLENE GLYCOL 4000
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: POLYVINYL ALCOHOL
avapritinib drug variants containing POLYVINYL ALCOHOL
| Company | Ingredient | NDC |
|---|---|---|
| Blueprint Medicines Corporation | avapritinib | 72064-110 |
| >Company | >Ingredient | >NDC |
avapritinib drug variants not containing POLYVINYL ALCOHOL
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: PROPYLENE GLYCOL
avapritinib drug variants containing PROPYLENE GLYCOL
| Company | Ingredient | NDC |
|---|---|---|
| Blueprint Medicines Corporation | avapritinib | 72064-110 |
| >Company | >Ingredient | >NDC |
avapritinib drug variants not containing PROPYLENE GLYCOL
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: SHELLAC
avapritinib drug variants containing SHELLAC
| Company | Ingredient | NDC |
|---|---|---|
| Blueprint Medicines Corporation | avapritinib | 72064-110 |
| >Company | >Ingredient | >NDC |
avapritinib drug variants not containing SHELLAC
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TALC
avapritinib drug variants containing TALC
| Company | Ingredient | NDC |
|---|---|---|
| Blueprint Medicines Corporation | avapritinib | 72064-110 |
| >Company | >Ingredient | >NDC |
avapritinib drug variants not containing TALC
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: TITANIUM DIOXIDE
avapritinib drug variants containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| Blueprint Medicines Corporation | avapritinib | 72064-110 |
| >Company | >Ingredient | >NDC |
avapritinib drug variants not containing TITANIUM DIOXIDE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
© Copyright 2002-2024 thinkBiotech LLC
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Preferred Citation:
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Links
Follow DrugPatentWatch:
